TELA Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TELA Bio, Inc. on September 27, 2021. The filing reports the appointment of a new Chief Financial Officer and Chief Operating Officer, effective immediately.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and personnel changes.
Material Changes
- Executive Appointment: Roberto Cuca was appointed as Chief Financial Officer (CFO) and Chief Operating Officer (COO), serving as the principal financial and accounting officer.
- Role Transition: Megan Smeykal, previously Vice President – Corporate Controller, ceased performing the duties of principal financial officer effective upon Mr. Cuca's appointment.
Compensation, Guidance, and Risks
Compensation Package:
- Base Salary: $425,000 annually.
- Bonus: Target annual bonus of 50% of base salary (not pro-rated for 2021).
- Equity Grant: An inducement grant of options to purchase 144,000 shares at an exercise price of $13.31. Vesting is 25% on the first anniversary, with the remaining 75% vesting in 36 equal monthly installments. The option expires on September 27, 2031.
Severance Provisions:
- Standard Termination: If terminated without "Cause" or resigns for "Good Reason," Mr. Cuca receives nine months of base salary severance and nine months of health benefits.
- Change of Control: If terminated without "Cause" or resigns for "Good Reason" during a change of control period, Mr. Cuca receives 12 months of base salary severance, a pro-rated bonus, and acceleration of service-vesting conditions for equity awards.
Outlook and Risks: The filing contains no financial guidance, management commentary on business outlook, or discussion of specific risks or contingencies beyond the standard employment agreement terms.
Key Facts for Investor Verification
- Verify the impact of the new CFO/COO leadership on the company's financial strategy and capital management.
- Review the full text of the Employment Agreement (Exhibit 10.1) for detailed definitions of "Cause," "Good Reason," and "Change of Control."
- Monitor the vesting schedule of the 144,000 share option grant and its potential dilution impact.
- Confirm the transition of duties from the former principal financial officer to ensure continuity in financial reporting.